​

Edwards Lifesciences (EW) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

EW Stock Forecast

Edwards Lifesciences (EW) stock forecast, based on 49 Wall Street analysts, predicts a 12-month average price target of $101.70, with a high of $110.00 and a low of $85.00. This represents a 17.60% increase from the last price of $86.48.

$60 $70 $80 $90 $100 $110 High: $110 Avg: $101.7 Low: $85 Last Closed Price: $86.48

EW Stock Rating

Edwards Lifesciences stock's rating consensus is Buy, based on 49 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 33 Buy (67.35%), 16 Hold (32.65%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 49 0 16 33 Strong Sell Sell Hold Buy Strong Buy

EW Price Target Upside V Benchmarks

TypeNameUpside
StockEdwards Lifesciences17.60%
SectorHealthcare Stocks 15.45%
IndustryMedical Device Stocks24.74%

Price Target Trends

1M3M12M
# Anlaysts-549
Avg Price Target-$103.40$96.31
Last Closing Price$86.48$86.48$86.48
Upside/Downside-19.57%11.37%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 264187--29
Sep, 264177--28
Aug, 264177--28
Jul, 264178--29
Jun, 264178--29
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 28, 2026UBS$110.00$83.0432.47%27.20%
Jul 24, 2026Piper Sandler$101.00$83.8220.50%16.79%
Jul 24, 2026Mike KratkyLeerink Partners$101.00$83.8220.50%16.79%
Jul 16, 2026Richard NewitterTruist Financial$95.00$86.799.46%9.85%
Jul 13, 2026RBC Capital$110.00$92.0319.53%27.20%
Jul 06, 2026Evercore ISI$100.00$93.127.39%15.63%
Jun 30, 2026Marie ThibaultBTIG$110.00$91.1820.64%27.20%
Apr 27, 2026Barclays$110.00$84.1530.72%27.20%
Apr 24, 2026Truist Financial$90.00$83.158.24%4.07%
Apr 24, 2026Vijay KumarEvercore ISI$93.00$83.1211.89%7.54%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 06, 2026BarclaysOverweightOverweightinitialise
Oct 05, 2026CitigroupBuyBuyhold
Jul 28, 2026UBSNeutralBuyupgrade
Jul 28, 2026UBSNeutralBuyinitialise
Jul 24, 2026Piper SandlerOverweightOverweighthold
Jul 21, 2026Cowen & Co.BuyBuyhold
Jul 13, 2026RBC CapitalOutperformOutperformhold
Jul 08, 2026CitigroupBuyBuyhold
Jul 06, 2026Evercore ISIOutperformOutperformhold
Jun 30, 2026BTIGBuyBuyhold

Financial Forecast

EPS Forecast

$1 $2 $3 $4 $5 $6 $7 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.41$2.46$2.31$6.98$1.84---
Avg Forecast$2.26$2.46$2.51$2.57$2.44$2.74$3.11$3.49
High Forecast$2.43$2.55$2.52$2.60$2.53$2.96$3.40$3.66
Low Forecast$2.14$2.40$2.48$2.42$2.42$2.41$2.82$3.44
Surprise %6.64%--7.97%171.60%-24.59%---

Revenue Forecast

$5B $6B $6B $7B $8B $9B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$5.23B$5.38B$5.01B$5.44B$6.07B---
Avg Forecast$5.26B$5.37B$5.97B$5.80B$5.82B$6.40B$7.09B$7.77B
High Forecast$5.55B$5.52B$6.00B$5.86B$5.86B$6.43B$7.16B$8.07B
Low Forecast$5.03B$5.26B$5.94B$5.33B$5.79B$6.37B$7.02B$7.69B
Surprise %-0.51%0.25%-16.07%-6.14%4.18%---

Net Income Forecast

$1B $2B $2B $3B $4B $5B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.50B$1.52B$1.40B$4.17B$1.07B---
Avg Forecast$1.39B$1.53B$1.40B$1.57B$1.51B$1.59B$1.89B$2.12B
High Forecast$1.67B$1.84B$1.68B$1.58B$1.54B$1.81B$2.07B$2.23B
Low Forecast$1.11B$1.22B$1.12B$1.47B$1.48B$1.47B$1.72B$2.09B
Surprise %8.09%-0.49%-166.36%-28.93%---

EW Forecast FAQ

Is Edwards Lifesciences stock a buy?

Edwards Lifesciences stock has a consensus rating of Buy, based on 49 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 33 Buy, 16 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Edwards Lifesciences is a favorable investment for most analysts.

What is Edwards Lifesciences's price target?

Edwards Lifesciences's price target, set by 49 Wall Street analysts, averages $101.7 over the next 12 months. The price target range spans from $85 at the low end to $110 at the high end, suggesting a potential 17.60% change from the previous closing price of $86.48.

How does Edwards Lifesciences stock forecast compare to its benchmarks?

Edwards Lifesciences's stock forecast shows a 17.60% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the medical device stocks industry (24.74%).

What is the breakdown of analyst ratings for Edwards Lifesciences over the past three months?

  • October 2026: 13.79% Strong Buy, 62.07% Buy, 24.14% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 14.29% Strong Buy, 60.71% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 14.29% Strong Buy, 60.71% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.

What is Edwards Lifesciences’s EPS forecast?

Edwards Lifesciences's average annual EPS forecast for its fiscal year ending in December 2026 is $2.74, marking a 48.91% increase from the reported $1.84 in 2025. Estimates for the following years are $3.11 in 2027, and $3.49 in 2028.

What is Edwards Lifesciences’s revenue forecast?

Edwards Lifesciences's average annual revenue forecast for its fiscal year ending in December 2026 is $6.4B, reflecting a 5.47% increase from the reported $6.07B in 2025. The forecast for 2027 is $7.09B, and $7.77B for 2028.

What is Edwards Lifesciences’s net income forecast?

Edwards Lifesciences's net income forecast for the fiscal year ending in December 2026 stands at $1.59B, representing an 47.82% increase from the reported $1.07B in 2025. Projections indicate $1.89B in 2027, and $2.12B in 2028.